Literature DB >> 12917624

SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo.

Soumen Chakraborty1, Kislay Kumar Sinha, Vitalyi Senyuk, Giuseppina Nucifora.   

Abstract

Acute myeloid leukemia 1 (AML1) belongs to a family of DNA-binding proteins highly conserved through evolution. AML1 regulates the expression of several hematopoietic genes and is essential for murine fetal liver hematopoiesis. We report here that the histone methyltransferase SUV39H1, a mammalian ortholog of the Drosophila melanogaster SU(VAR) 3-9, forms complex with AML1. SUV39H1 methylates lysine 9 of the histone protein H3 leading to the formation of the high-affinity binding site on chromatin for proteins of the heterochromatin protein 1 family (HP1). The interaction of AML1 with SUV39H1 requires the N-terminus of AML1 where the Runt domain is located. Binding of AML1 to SUV39H1 abrogates the transactivating and DNA-binding properties of AML1 and dissociates the net-like nuclear structure of AML1. It has been reported that AML1 is capable of interaction with histone acetyl transferases (CBP, p300, and MOZ) and with component of the histone deacetylase complex (Sin3), and that the interaction with these coregulators affects the strength of AML1 in promoter regulation. Our data suggest that other enzymes are also involved in gene regulation by AML1 activity by modulating the affinity of AML1 for DNA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917624     DOI: 10.1038/sj.onc.1206600

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  RUNX1 regulates corepressor interactions of PU.1.

Authors:  Zhenbo Hu; Xiaorong Gu; Kristine Baraoidan; Vinzon Ibanez; Arun Sharma; ShriHari Kadkol; Reinhold Munker; Steven Ackerman; Giuseppina Nucifora; Yogen Saunthararajah
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.

Authors:  Gang Huang; Xinghui Zhao; Lan Wang; Shannon Elf; Hao Xu; Xinyang Zhao; Goro Sashida; Yue Zhang; Yan Liu; Jennifer Lee; Silvia Menendez; Youyang Yang; Xiaomei Yan; Pu Zhang; Daniel G Tenen; Motomi Osato; James J-D Hsieh; Stephen D Nimer
Journal:  Blood       Date:  2011-10-19       Impact factor: 22.113

Review 3.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 4.  Sound of silence: the properties and functions of repressive Lys methyltransferases.

Authors:  Chiara Mozzetta; Ekaterina Boyarchuk; Julien Pontis; Slimane Ait-Si-Ali
Journal:  Nat Rev Mol Cell Biol       Date:  2015-08       Impact factor: 94.444

Review 5.  Roles of repressive epigenetic machinery in lineage decision of T cells.

Authors:  Taku Naito; Ichiro Taniuchi
Journal:  Immunology       Date:  2013-06       Impact factor: 7.397

6.  Identification and characterization of a highly conserved crenarchaeal protein lysine methyltransferase with broad substrate specificity.

Authors:  Yindi Chu; Zhenfeng Zhang; Qian Wang; Yuanming Luo; Li Huang
Journal:  J Bacteriol       Date:  2012-10-19       Impact factor: 3.490

7.  Plant homeodomain finger protein 2 promotes bone formation by demethylating and activating Runx2 for osteoblast differentiation.

Authors:  Hye-Jin Kim; Jong-Wan Park; Kyoung-Hwa Lee; Haejin Yoon; Dong Hoon Shin; Uk-Il Ju; Seung Hyeok Seok; Seung Hyeon Lim; Zang Hee Lee; Hong-Hee Kim; Yang-Sook Chun
Journal:  Cell Res       Date:  2014-09-26       Impact factor: 25.617

8.  The core binding factor CBF negatively regulates skeletal muscle terminal differentiation.

Authors:  Ophélie Philipot; Véronique Joliot; Ouardia Ait-Mohamed; Céline Pellentz; Philippe Robin; Lauriane Fritsch; Slimane Ait-Si-Ali
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

9.  PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.

Authors:  Hee-Jun Wee; Dominic Chih-Cheng Voon; Suk-Chul Bae; Yoshiaki Ito
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 10.  Post-translational modifications of Runx1 regulate its activity in the cell.

Authors:  Lan Wang; Gang Huang; Xinyang Zhao; Megan A Hatlen; Ly Vu; Fan Liu; Stephen D Nimer
Journal:  Blood Cells Mol Dis       Date:  2009-04-21       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.